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Obesity is commonplace, and surgical treatment usually includes Roux-en-Y gastric bypasses (RYGBs). RYGBs have the most
documented side effects including vitamin deficiencies, rebound weight gain, and symptomatic hypoglycemia; fewer series exist
describing hypoglycemia following other bariatric operations. We reviewed all patients undergoing laparoscopic adjustable gastric
banding (LAGB) at our institution between 2008 and 2012. Three patients were identified to have symptomatic hypoglycemia
following LAGB. Mean time from surgery was 33 months (range 14–45 months), and mean weight loss was 32.7 kg (range 15.9–
43.1 kg). None of the patients had preexisting diabetes. Therefore, symptomatic hypoglycemia should be investigated irrespective
of bariatric operation.
1. Introduction
Obesity is one of the biggest health issues facing medicine.
Diet and medication programs alone are often unable to
maintain durable weight loss; thus, bariatric surgery has
proven to provide long-term weight loss that corresponds to
reduced mortality [1, 2]. The mainstay of bariatric surgery is
the Roux-en-Y gastric bypass (RYGB), which has to date the
most durable, documented long-term weight loss. However,
long-term complications include nutrient deficiencies, her-
nias, excess skin, neuropathic changes, and hyperinsulinism
[3]. One of the most striking side effects of this particular
surgery is postgastric bypass hypoglycemia. Theories exist
regarding the underlying etiology for this postgastric bypass
hypoglycemia including both pancreatic-mediated (beta-
cell) and nonpancreatic mediated mechanisms.
Briefly speaking, the pancreatic mediated (beta-cell)
mechanisms include the following mechanisms (1) enhanced
insulin sensitivity, (2) increased density of insulin islets,
and (3) enhanced hormonal secretion in the bypassed limb
[4]. On the other hand, nonpancreatic mechanisms have
included the following mechanisms: (1) decreased levels
of the appetite-stimulating and insulin counter-regulatory
gastrointestinal hormone, ghrelin, and (2) alterations in other
counter regulatory hormones [5]. More recently, Rabiee et
al. [4] have suggested that it is the persistent exaggerated
hypersecretion of GLP-1, which has previously shown to
be insulinotropic, insulinomimetic, and glucagonostatic.The
overexpression of the islet cell transcription factor, PDX-
1, caused by prolonged hypersecretion of GLP-1 causes the
hypoglycemia [4]. The most likely explanation is that it is
not just one of the aforementioned mechanisms solely but
a combination of beta-cell proliferation, an alteration of the
hormonalmilieu, and associated anatomicalmechanisms [5].
2. Case Presentation
As a whole, there are not many recently reported cases
explaining hypoglycemia following other bariatric surgical
treatments, specifically laparoscopic adjustable gastric band-
ing (LAGB). Therefore, under our own institution’s review
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board approved protocol, we reviewed all patients undergo-
ing LAGB between 2008 and 2012 at our institution. These
patients were identified retrospectively from a prospective,
longitudinal bariatric outcomes database. All patients had
met the criteria for bariatric surgery established by the
National Institutes of Health Consensus Development Panel,
having a body mass index (BMI) of ≥40 kg/m2 or ≥35 kg/m2
with obesity-related comorbidities.
All of the patients within this program and database had
at least one previously failed 6-month attempt to maintain
weight loss through nonsurgical means. Nutritional and psy-
chiatric approvals were also required; patients deemed unfit
for weight loss surgery from nutritional and psychological
standpoints did not receive surgery. For all LAGB cases, the
Lap-Band system (Allergan, Santa Barbara, CA) was placed
by experienced surgeons using the pars flaccida technique
[6]. Weight loss was expressed as percent excess body weight
loss [7], while overall glucosemeasurements were taken at the
discretion of the provider.
Three patients were identified. Demographics and clinical
characteristics of the three patients are described in Table 1.
As a whole, none of the patients were on prescribed med-
ications that may have had insulinomimetic mechanisms.
As a whole, all there had a positive Whipple test. A Whip-
ple test consists of the following entities: (1) symptoms of
hypoglycemia, (2) low plasma glucose (<55mg/dL) at the
time of symptoms, (3) relief of symptoms with the correction
of low glucose, as well as concomitant measurement of
serum insulin (>3 𝜇U/mL), C-peptide (0.6 ng/mL), and (4) a
negative sulfonylurea screen [8]. Mean age at time of surgery
was 52 years (range 47–57 years).Themean time from surgery
to the development of symptoms was 33months (range 14–45
months). Mean weight loss at time of symptoms was 32.7 kg
(range 21–43.2 kg). None of the patients had a preexisting
diagnosis of type II diabetes mellitus (DM), but one patient
did record his own blood glucose levels for trends (Figure 1).
The individual characteristics of each patient are
described as follows. Patient 1 was a female. She was 57
at the time of her operation, and her preoperative profile
included a body mass index (BMI) of 47 kg/m2. Preoperative
medications included citalopram and zolpidem. The
patient underwent a LAGB operation with concomitant
hiatal hernia repair. Her perioperative course was benign.
Symptoms appeared 45 months following the surgery. Her
weight loss was 38.2 kg (84 lbs) when symptoms appeared
and 0mL was present in band reservoir.
Patient 2 was also a female. She was 47 at the time
of her operation. Her preoperative profile included a BMI
of 40.2 kg/m2. Preoperative medications included Seroquel,
Wellbutrin, and Saphris.This patient also underwent a LAGB,
and her perioperative course was also benign. Symptoms
appeared 41 months following surgery. Her weight loss was
approximately 43.2 kg (95 lbs) when symptoms appeared and
5.1mL was present in band reservoir.
Patient 3 was a male, and this patient was 52 at the time of
his operation. Preoperative BMI was 40.9 kg/m2. Preopera-
tive medications included Zocor, Avalide, Tricor, and Aspirin
(ASA). The patient underwent LAGB. He was admitted
postoperatively for a partial small bowel obstruction (SBO);
Table 1: Case patients’ characteristics.
Variables Patient1
Patient
2
Patient
3
Age (years) 57 47 52
Gender (male, female) F F M
Preoperative BMI (kg/m2) 47 40.2 40.9
Medication-related complications N N N
History of type II diabetes mellitus N N N
LAGB placement Y Y Y
Concomitant hiatal hernia repair Y N N
Presence of perioperative complications N N N
Time to development of symptoms (mo.) 45 41 14
Presence of Whipple’s triad Y Y Y
Weight loss at time of symptoms (kg) −38.2 −43.2 −21
Volume of band reservoir (mL) 0 5.1 8.2
BMI: body mass index; LAGB: laparoscopic adjustable gastric banding; mo.:
months; kg: kilograms; mL: milliliters.
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Figure 1: Trend in nonfasting blood glucose level of a single patient
with LAGB.
this episode resolved with nonoperative management. His
symptoms appeared 14 months following the surgery. The
patient was seen in the emergency room for blood glucose
of 42mg/dL which resolved with the administration of
dextrose-containing solutions. At the time, his weight loss
was approximately 21 kg (47.5 lbs) and 8.2mL was present in
band reservoir.
3. Discussion
Herein, we investigate and review the literature regard-
ing symptomatic hypoglycemia following bariatric surgery,
specifically as it relates to LAGB, as well as to bariatric surgery
as a whole. This report has identified 3 patients who had
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symptomatic hypoglycemia following LAGB. Our patients’
symptoms developed, on average, 33 months following the
surgery, with the earliest symptoms being documentedwithin
the first 14 months. In this particular patient, his symptoms
were not associated with his maximum net weight loss.
Collectively, all three patients had similar preoperative body
mass indexes (BMI), but, on average, the females (1) took
a longer time to achieve substantial weight loss and (2) the
development of their symptoms, from the time of the surgery,
was longer.
The current literature estimates the overall incidence
of reported postprandial hypoglycemia following RYGB to
be approximately 1% [9]. Alterations in the volume placed
within the band reservoir seemed to have no influence on the
development of these symptoms, nor their frequency, in these
three patients, and subsequent reports have corroborated
these findings. None of the patients had preexisting diabetes
mellitus (DM). This finding is congruent with previous
reports from both Goldfine et al. [3] andMarsk et al. [9] who
commented that there is no observable association between
preoperative diagnosis of DM and the development of these
symptoms. In fact, the overall proportion of persons with
diabetes mellitus who undergo bariatric surgery and develop
this complication is surprisingly low.
Overall, there are mixed reviews of hypoglycemic events
following gastric banding procedures. We acknowledge that
gastric banding does not alter absorption and is purely
restrictive; yet, it has produced similar symptoms to other
bariatric procedures which are both malabsorptive and
restrictive. In juxtaposition to our study of three patients,
Marsk et al. [9] reported that there were no appreciable differ-
ences in hypoglycemic episodes for their cohort of banding
patients versus a reference cohort population. Scavini et al.
[10] reviewed their 222 cases of gastric bands and found a 3%-
4% (𝑛 = 8 patients) rate of asymptomatic hyperinsulinemic
hypoglycemia; they attributed this to the reduction of body
mass index (BMI) and the inherent improvement in insulin
sensitivity. In review of our cohort, our patients’ episodes
occurred independently of their maximum net BMI reduc-
tion, and thus, may not be entirely due to an improvement in
insulin sensitivity.
Only one patient in our study had a concomitant hiatal
hernia repair which may have portended more manipulation
of the vagus nerve, thus, inadvertent regulation of gastric
hormones. Historically, procedures associated with greater
manipulation of the vagus nerve have included esophagec-
tomies, gastrectomies, RYGB, and Billroth configurations;
they all reroute the foregut anatomy [11]. Interestingly
enough, upon review of other reported LAGB studies, these
studies have investigated long-term weight regulating effects
of vagotomy when performed in conjunction with gastric
banding, however, not specifically hypoglycemia [12–15].
The symptoms of hypoglycemia may be debilitating
and often invoke other treatment measures; often even the
treatments do not fully reverse the symptomatology. Patients
are often subjected to invasive testing to determine whether
there is a component of segmental hyperinsulinemic response
to ingested meals; intra-arterial calcium-stimulated selective
hepatic venous sampling allows the practitioner to determine
whether there is a component B-cell hyperplasia with associ-
ated high calcium-stimulated insulin gradient [16].
Hypoglycemic episodes follow meals and are often resis-
tant to changes in character of meals. All the patients
reported symptoms consistent with Whipple’s triad, and one
patient’s hypoglycemia required a subsequent admission to
the hospital. A positive Whipple’s triad is often inherent
in cases: (1) symptoms of hypoglycemia following a meal,
(2) documentation of hypoglycemia, and (3) symptoms
relieved by the administration of glucose [8, 11]. For example,
despite “normal glucose” values (see Figure 1), our third
patient met criteria forWhipple’s triad onmultiple occasions.
The episodes should not be confused with “reactive hypo-
glycemia;” these symptoms can be ameliorated with changes
in diet volume and carbohydrate percentage [17, 18].
Furthermore, the timing of these symptoms does not cor-
relate withweight loss or overall associated nutrition changes.
As mentioned previously, our patients’ symptoms developed,
on average, 33 months following the surgical intervention,
and this is congruent with other studies. Known cases
of hyperinsulinemic neuroglycopenia have often developed
very late, ranging from 1 to 9 years following RYGB (typically
2–4 years); at this time, cell adaptation to the postoperative
milieu, as well as some renewed insulin resistance from
incipient weight regain, should have reduced the likelihood
of excessive insulin secretion [19].
There are a host of available treatments that are noninva-
sive and invasive depending on the severity and chronicity of
symptoms. Available treatments include (1) very low-carbo-
hydrate diets; (2) diazoxide, acarbose, and octreotide; and (3)
subtotal pancreatectomy [16]. According toMcLaughlin et al.
[16], they placed a gastrostomy into the remnant stomach to
alter delivery of nutrients, while not compounding the hyper-
insulin versus dysregulated B-cell’s response. It appears that
the treatments may be suboptimal and none were applied to
LAGB as it does not alter the anatomical configuration of the
bowel present, nor should it alter the delivery of postprandial,
regulatory hormones. As it pertains to nutritional changes
and vitamin supplementation, supplements for iron, calcium,
Vitamin B12, folate, and selenium should still be given to
LAGB patients given the overall reduced caloric intake [20].
4. Conclusion
We continue to recommend that symptomatic hypoglycemia
be investigated irrespective of bariatric surgery performed.
Further studies are needed to ascertain the etiology of
hypoglycemia in LAGB patients on a larger scale.
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